Clinical study on the therapeutic efficacy of Edaravone in acute cerebral infarction

doi:10.3877/cma.j.issn.2095-123X.2019.02.004

Abstract

Abstract:

Objective

To investigate the effect and safety of edavarone in the treatment of acute cerebral infarction.

Methods

Totally, 120 patients, admitted to Department of Neurology of Yanbian University Hospital from January 2018 to January 2019, were randomly divided into control group (60 cases) and observation group (60 cases). Both groups were given conventional treatment, but the patients in observation group were given edaravone additonally. On 14 and 21 d after treatment, the clinical effect was evaluated using the chart of ADL and NIHSS.

Results

The therapeutic effective rates were 88.33% and 73.33% for observation group and control group, respectively. Meanwhile, significant improvement could be seen by the score of ADL and NIHSS on day 7 and day 14 after treatment in observation group, and there was significant difference between these two groups. More, no severe drug associated side-effect were observed in each group.

Conclusion

Edavarone can improve neurological deficits as well ADL score in acute cerebral infarction patients, resulting in good therapeutic efficacy, and it is worth of application as a safe drug.

Key words: Edaravone, Acute cerebral infarction, Neurological function deficits

Linlin Lyu, Yingjun Zhu. Clinical study on the therapeutic efficacy of Edaravone in acute cerebral infarction[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2019, 09(02): 79-81.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2019.02.004

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2019/V09/I02/79

Figures/Tables 2

References 16

[1]	Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling[J]. Lancet Neurol, 2009, 8(4): 345-354.
[2]	王允，代大伟，范宇威,等.急性脑梗死溶栓治疗的临床进展[J].现代生物医学进展, 2017, 17(26): 5194-5196.
[3]	杨善进，王兴元.依达拉奉治疗急性脑梗死效果分析[J].医学理论与实践, 2018, 31(19): 2890-2891.
[4]	赵晓英，白福海，王强.依达拉奉在器官保护中的作用及研究进展[J].麻醉安全与质控, 2018, 2(2): 107-112.
[5]	中华神经科学会，中华神经外科学会.脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志, 1996, 29(6): 381-383.
[6]	雷华，张明.依达拉奉对急性脑梗死患者日常生活能力和神经功能的影响[J].河北医学, 2015, 21(5): 752-754.
[7]	杨嵩，储照虎.急性脑梗死溶栓治疗的现状与进展[J].医学信息, 2016, 29(6): 39-40.
[8]	骆海坤，袁耀辉，王丽华.自由基清除剂依达拉奉的作用机制及临床应用[J].北方药学, 2018, 15(6): 138-139.
[9]	Okamura K, Tsubokawa T, Johshita H, et al. Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia[J]. Neurol Res, 2014, 36(1): 65-69.
[10]	林思宁，李建民，刘俊杰,等.依达拉奉对大鼠颅脑创伤后神经元凋亡的影响[J].安徽医科大学学报, 2018, 53(5): 676-679.
[11]	马宝林，林吴用，高丽丽.依达拉奉对大鼠脑出血后脑水肿及脂质过氧化的影响[J].中国生化药物杂志, 2016, 36(8): 40-42.
[12]	陈冬丽.依达拉奉对急性脑梗死患者血清炎性因子及脑血流的影响[J].中国实用神经疾病杂志, 2016, 19(1): 116-117.
[13]	来峰.依达拉奉注射液治疗缺血性脑卒中的效果及作用机制探析[J].中国处方药, 2018, 16(11): 80-81.
[14]	朱国光.依达拉奉治疗急性脑梗死的临床效果及不良反应率分析[J].临床医药文献电子杂志, 2018, 5(89): 47, 49.
[15]	漆伟男.依达拉奉治疗急性脑梗死的疗效分析[J].中国现代医生, 2017, 55(27): 49-51.
[16]	周峰，马黎，傅国萍,等.依达拉奉在预防控制脑梗死患者感染发生及免疫调节中的作用[J].中华医院感染学杂志, 2017, 27(12): 2710-2713.

组别	例数	基本痊愈	好转	进步	无效	总有效率
观察组	60	20	18	15	7	53（88.33%）
对照组	60	12	10	22	16	44（73.33%）
χ²值	?	?	?	?	?	4.356
P值	?	?	?	?	?	0.037

组别	例数	基本痊愈	好转	进步	无效	总有效率
观察组	60	20	18	15	7	53（88.33%）
对照组	60	12	10	22	16	44（73.33%）
χ²值	?	?	?	?	?	4.356
P值	?	?	?	?	?	0.037

组别	例数	ADL评分			NIHSS评分
组别	例数	治疗前	治疗后7 d	治疗后14 d	治疗前	治疗后7 d	治疗后14 d
观察组	60	46.275±5.345	67.515±6.920	83.728±10.104	34.331±5.801	20.910±4.333	6.641±4.774
对照组	60	47.404±5.538	56.617±5.639	70.316±8.809	34.122±5.710	26.725±4.982	13.972±5.314
t值	?	0.081	8.162	7.343	4.092	11.341	14.526
P值	?	0.601	0.014	0.024	0.576	0.025	0.011

组别	例数	ADL评分			NIHSS评分
组别	例数	治疗前	治疗后7 d	治疗后14 d	治疗前	治疗后7 d	治疗后14 d
观察组	60	46.275±5.345	67.515±6.920	83.728±10.104	34.331±5.801	20.910±4.333	6.641±4.774
对照组	60	47.404±5.538	56.617±5.639	70.316±8.809	34.122±5.710	26.725±4.982	13.972±5.314
t值	?	0.081	8.162	7.343	4.092	11.341	14.526
P值	?	0.601	0.014	0.024	0.576	0.025	0.011

Please choose a citation manager

Content to export